ABSTRACT
Mast cells are long-lived cells that are principally recognized for their effector function in helminth infections and allergic reactions. These cells are derived from pluripotential hematopoietic stem cells in the bone marrow that give rise to committed mast cell progenitors in the blood and are recruited to tissues, where they mature. Little is known about the chemotactic signals responsible for recruitment of progenitors and localization of mature mast cells. A mouse model was set up to identify possible mast cell progenitor chemoattractants produced during repeated allergen challenge in vivo. After the final challenge, the nasal mucosa was removed to produce conditioned medium, which was tested in chemotaxis assays against 2-wk murine bone marrow-derived c-kit+ mast cells (BMMC). A single peak of chemotactic activity was seen on reverse-phase HPLC with a retention time and electrospray mass spectrum consistent with prostaglandin E2 (PGE2). This lipid was found to be a highly potent chemoattractant for immature (2-wk) and also mature (10-wk) BMMC in vitro. Fluorescently labeled 2-wk c-kit+ BMMC, when injected intravenously, accumulated in response to intradermally injected PGE2. Analysis using TaqMan showed mRNA expression of the PGE2 receptors 3 (EP3) and 4 (EP4) on 2- and 10-wk BMMC. Chemotaxis induced by PGE2 was mimicked by EP3 agonists, blocked by an EP3 receptor antagonist, and partially inhibited by a MAPKK inhibitor. These results show an unexpected function for PGE2 in the chemotaxis of mast cells.
Subject(s)
Chemotaxis/physiology , Dinoprostone/metabolism , Dinoprostone/physiology , Mast Cells/metabolism , Receptors, Prostaglandin E/physiology , Animals , Cell Differentiation/physiology , Cells, Cultured , Chemotactic Factors/physiology , Mast Cells/cytology , Mice , Mice, Inbred BALB C , Ovalbumin/immunology , Receptors, Prostaglandin E, EP3 SubtypeABSTRACT
BACKGROUND: Little is known about the mechanisms that regulate the selective recruitment of basophils to sites of allergic inflammation. OBJECTIVE: Here we examine the role of stem cell factor (SCF) in the regulation of basophil function. METHODS: Human basophils were isolated from peripheral blood, and their migration was investigated in chemotaxis assays. Apoptosis was detected by means of annexin V and propidium iodide staining. The expression of cell-surface molecules was measured by means of flow cytometry. RESULTS: SCF amplified the chemotactic responsiveness of human peripheral blood basophils to the chemoattractants eotaxin, monocyte chemotactic protein 2 and macrophage inflammatory protein 1alpha, and C5a, without being chemotactic or chemokinetic by itself. SCF synergized with chemoattractants in causing basophil upregulation of the integrin CD11b, and this effect was inhibited by a c-kit antibody, the tyrosine kinase inhibitor imatinib mesylate (STI-571), and a phosphatidylinositol 3 kinase inhibitor but not by inhibitors of p38 mitogen-activated protein kinase or mitogen-activated protein kinase/extracellular signal-regulated kinase kinase. Basophils bound fluorescence-labeled SCF and expressed its receptor, c-kit, which was markedly upregulated in culture for 24 to 48 hours in the presence of IL-3. Moreover, SCF prolonged basophil survival in concert with IL-3 by delaying apoptosis. These effects of SCF were selective for basophils because chemotaxis and CD11b upregulation of eosinophils or neutrophils were unchanged. CONCLUSION: SCF might be an important selective modulator of basophil function through a phosphatidylinositol 3 kinase-dependent pathway.
Subject(s)
Basophils/drug effects , Integrins/metabolism , Stem Cell Factor/pharmacology , Basophils/cytology , Basophils/physiology , CD11b Antigen/metabolism , Cell Survival/drug effects , Chemokine CCL11 , Chemokine CCL4 , Chemokine CCL8 , Chemokines, CC/administration & dosage , Chemotactic Factors/administration & dosage , Chemotaxis, Leukocyte/drug effects , Complement C5a/administration & dosage , Drug Synergism , Humans , In Vitro Techniques , Interleukin-3/administration & dosage , Macrophage Inflammatory Proteins/administration & dosage , Monocyte Chemoattractant Proteins/administration & dosage , Proto-Oncogene Proteins c-kit/metabolism , Signal Transduction/drug effects , Stem Cell Factor/administration & dosage , Up-Regulation/drug effectsABSTRACT
Mast cells are tissue-resident cells with important functions in allergy and inflammation. Pluripotential hematopoietic stem cells in the bone marrow give rise to committed mast cell progenitors that transit via the blood to tissues throughout the body, where they mature. Knowledge is limited about the factors that release mast cell progenitors from the bone marrow or recruit them to remote tissues. Mouse femoral bone marrow cells were cultured with IL-3 for 2 wk and a range of chemotactic agents were tested on the c-kit(+) population. Cells were remarkably refractory and no chemotaxis was induced by any chemokines tested. However, supernatants from activated mature mast cells induced pronounced chemotaxis, with the active principle identified as leukotriene (LT) B(4). Other activation products were inactive. LTB(4) was highly chemotactic for 2-wk-old cells, but not mature cells, correlating with a loss of mRNA for the LTB(4) receptor, BLT1. Immature cells also accumulated in vivo in response to intradermally injected LTB(4). Furthermore, LTB(4) was highly potent in attracting mast cell progenitors from freshly isolated bone marrow cell suspensions. Finally, LTB(4) was a potent chemoattractant for human cord blood-derived immature, but not mature, mast cells. These results suggest an autocrine role for LTB(4) in regulating tissue mast cell numbers.
Subject(s)
Bone Marrow Cells/cytology , Chemotaxis/physiology , Interleukin-3/metabolism , Leukotriene B4/metabolism , Mast Cells/metabolism , Animals , Bone Marrow Cells/metabolism , Chemotactic Factors/isolation & purification , Chemotactic Factors/pharmacology , Chemotaxis/drug effects , Chromatography, High Pressure Liquid , DNA Primers , Enzyme-Linked Immunosorbent Assay , Fetal Blood/cytology , Flow Cytometry , Fluorescent Antibody Technique , Humans , Leukotriene B4/pharmacology , Mast Cells/drug effects , Mice , Receptors, Leukotriene B4 , Receptors, Purinergic P2/metabolism , Reverse Transcriptase Polymerase Chain ReactionABSTRACT
In a search for novel leukocyte chemoattractants at sites of allergic inflammation, we found basophil-selective chemoattractant activity in extracts of human nasal polyps. The extracts were fractionated by reverse phase HPLC, and the resulting fractions were tested for leukocyte-stimulating activity using sensitive shape change assays. The basophil-selective activity detected was not depleted by a poxvirus CC-chemokine-binding protein affinity column. This activity was further purified by HPLC, and proteins in the bioactive fractions were analyzed by tandem electrospray mass spectrometry. Insulin-like growth factor-2 (IGF-2) was identified in these HPLC fractions, and the basophil-stimulating activity was inhibited by an anti-IGF-2-neutralizing Ab. Recombinant IGF-2 induced a substantial shape change response in basophils, but not eosinophils, neutrophils, or monocytes. IGF-2 stimulated chemokinesis of basophils, but not eosinophils or neutrophils, and synergized with eotaxin-1/CCL11 in basophil chemotaxis. IGF-2 also caused up-regulation of basophil CD11b expression and inhibited apoptosis, but did not stimulate degranulation or Ca(2+) flux. Recombinant IGF-1 exhibited similar basophil-selective effects as IGF-2, and both growth factors were detected in nasal polyp extracts by ELISA. This is the first demonstration of chemokinetic factors that increase the motility of basophils, but do not act on other granulocytes or monocytes. IGF-1 and IGF-2 could play a role in the selective recruitment of basophils in vivo.
Subject(s)
Basophils/physiology , Chemotactic Factors/isolation & purification , Chemotaxis, Leukocyte/physiology , Insulin-Like Growth Factor II/isolation & purification , Insulin-Like Growth Factor I/isolation & purification , Nasal Polyps/metabolism , Amino Acid Sequence , Basophils/cytology , Cell Shape/physiology , Cell-Free System/physiology , Chemokine CCL11 , Chemokines, CC/pharmacology , Chemotactic Factors/physiology , Chromatography, High Pressure Liquid , Chromatography, Ion Exchange , Down-Regulation , Electrophoresis, Polyacrylamide Gel , Enzyme-Linked Immunosorbent Assay , Humans , Insulin-Like Growth Factor I/physiology , Insulin-Like Growth Factor II/physiology , Molecular Sequence Data , Nasal Polyps/pathology , Receptors, CCR3 , Receptors, Chemokine/antagonists & inhibitors , Receptors, Chemokine/biosynthesis , Recombinant Proteins/pharmacology , Up-RegulationABSTRACT
PGD(2), a major mast cell mediator, is a potent eosinophil chemoattractant and is thought to be involved in eosinophil recruitment to sites of allergic inflammation. In plasma, PGD(2) is rapidly transformed into its major metabolite delta(12)-PGJ(2), the effect of which on eosinophil migration has not yet been characterized. In this study we found that delta(12)-PGJ(2) was a highly effective chemoattractant and inducer of respiratory burst in human eosinophils, with the same efficacy as PGD(2), PGJ(2), or 15-deoxy-delta(12,14)-PGJ(2). Moreover, pretreatment of eosinophils with delta(12)-PGJ(2) markedly enhanced the chemotactic response to eotaxin, and in this respect delta(12)-PGJ(2) was more effective than PGD(2). delta(12)-PGJ(2)-induced facilitation of eosinophil migration toward eotaxin was not altered by specific inhibitors of intracellular signaling pathways relevant to the chemotactic response, phosphatidylinositol 3-kinase (LY-294002), mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (U-0126), or p38 mitogen-activated protein kinase (SB-202190). Desensitization studies using calcium flux suggested that delta(12)-PGJ(2) signaled through the same receptor, CRTH2, as PGD(2). Finally, delta(12)-PGJ(2) was able to mobilize mature eosinophils from the bone marrow of the guinea pig isolated perfused hind limb. Given that delta(12)-PGJ(2) is present in the systemic circulation at relevant levels, a role for this PGD(2) metabolite in eosinophil release from the bone marrow and in driving eosinophil recruitment to sites of inflammation appears conceivable.
Subject(s)
Bone Marrow Cells/metabolism , Chemotaxis, Leukocyte/physiology , Eosinophils/metabolism , Inflammation Mediators/physiology , Prostaglandin D2/analogs & derivatives , Prostaglandin D2/physiology , Aniline Compounds/pharmacology , Animals , Antigens, CD/biosynthesis , Basophils/drug effects , Basophils/metabolism , Basophils/physiology , Bone Marrow Cells/drug effects , Bone Marrow Cells/physiology , Calcium/metabolism , Calcium Signaling/drug effects , Cell Size/drug effects , Cell Size/physiology , Chemotaxis, Leukocyte/drug effects , Eosinophils/drug effects , Eosinophils/physiology , Female , Fluorescent Dyes/pharmacology , Guinea Pigs , Hindlimb , Humans , Inflammation Mediators/administration & dosage , Inflammation Mediators/blood , Male , Perfusion , Platelet Membrane Glycoproteins/biosynthesis , Prostaglandin D2/administration & dosage , Prostaglandin D2/blood , Respiratory Burst/drug effects , Respiratory Burst/physiology , Tetraspanin 30 , Xanthenes/pharmacologyABSTRACT
We investigated the actions of a panel of nonsteroidal anti-inflammatory drugs on eosinophils, basophils, neutrophils, and monocytes. Indomethacin alone was a potent and selective inducer of eosinophil and basophil shape change. In eosinophils, indomethacin induced chemotaxis, CD11b up-regulation, respiratory burst, and L-selectin shedding but did not cause up-regulation of CD63 expression. Pretreatment of eosinophils with indomethacin also enhanced subsequent eosinophil shape change induced by eotaxin, although treatment with higher concentrations of indomethacin resulted in a decrease in the expression of the major eosinophil chemokine receptor, CCR3. Indomethacin activities and cell selectivity closely resembled those of prostaglandin D(2) (PGD(2)). Eosinophil shape change in response to eotaxin was inhibited by pertussis toxin, but indomethacin- and PGD(2)-induced shape change responses were not. Treatment of eosinophils with specific inhibitors of phospholipase C (U-73122), phosphatidylinositol 3-kinase (LY-294002), and p38 mitogen-activated protein kinase (SB-202190) revealed roles for these pathways in indomethacin signaling. Indomethacin and its analogues may therefore provide a structural basis from which selective PGD(2) receptor small molecule antagonists may be designed and which may have utility in the treatment of allergic inflammatory disease.
Subject(s)
Basophils/metabolism , Chemokines, CC/metabolism , Eosinophils/metabolism , Indomethacin/pharmacology , Prostaglandin D2/metabolism , Antigens, CD/metabolism , Basophils/drug effects , Chemokine CCL11 , Chemotaxis, Leukocyte/drug effects , Chromones , Enzyme Inhibitors/pharmacology , Eosinophils/drug effects , Estrenes/pharmacology , Humans , Imidazoles/pharmacology , Macrophage-1 Antigen/metabolism , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Morpholines , Pertussis Toxin , Phosphoinositide-3 Kinase Inhibitors , Platelet Membrane Glycoproteins/metabolism , Pyridines/pharmacology , Pyrrolidinones/pharmacology , Respiratory Burst , Tetraspanin 30 , Type C Phospholipases/antagonists & inhibitors , Up-Regulation , Virulence Factors, Bordetella/pharmacology , p38 Mitogen-Activated Protein KinasesABSTRACT
Cooperative action of inflammatory mediators and adhesion molecules orchestrates eosinophil recruitment during allergic inflammation in the airways. This study investigated the mechanisms involved in increasing eosinophil adhesion to human bronchial epithelial cells (HBEC) following priming and activation of eosinophils with TNF-alpha and complement protein C5a, respectively. Under primed conditions, eosinophil adhesion increased 3-fold from basal (16%), and the effect was significantly greater (p < 0.05) than the increase following stimulation with C5a alone (2-fold). Eosinophil contact with HBEC was essential for priming. In contrast to C5a, adhesion of eotaxin-stimulated eosinophils to HBEC was not primed with TNF-alpha nor IL-5, a known eosinophil-priming agent. Priming caused activation of alpha(M)beta(2) integrin; mAb against either the common beta(2) integrin subunit or its ICAM-1 ligand reduced the primed component of adhesion. Using mAbs against beta(1) or alpha(5), but not alpha(4) integrin subunit, together with anti-beta(2) integrin mAb, reduced stimulated adhesion to basal levels. Cross-linking alpha(5)beta(1) integrin increased alpha(M)beta(2) integrin-dependent adhesion of eosinophils. There are no known adhesion molecule ligands of alpha(5)beta(1) integrin expressed on HBEC; however, fibronectin, the major matrix protein ligand for alpha(5)beta(1) integrin, was detected in association with HBEC monolayers. A mAb against fibronectin, in combination with anti-beta(2) integrin mAb, reduced adhesion to basal levels. In conclusion, alpha(5)beta(1) integrin may provide a contact-dependent costimulus for eosinophil priming that, together with TNF-alpha, potentiated C5a activation of alpha(M)beta(2) integrin and increased eosinophil adhesion to ICAM-1. Fibronectin, associated with HBEC, may act as a ligand for alpha(5)beta(1) integrin. Dual regulation of eosinophil priming may prevent inappropriate activation of eosinophils in the circulation.